- Conditions
- Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver
- Interventions
- OA-235i (4 mg), OA-235i (8 mg), OA-235i (16 mg), OA-235i (30 mg), OA-235i (40 mg), OA-235i or placebo
- Drug
- Lead sponsor
- Oasis Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 307
matching trials from the live ClinicalTrials.gov search.
Filters: Condition: NASH - Nonalcoholic Steatohepatitis; NAFLD - Nonalcoholic Fatty Liver Disease Clear all
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- EFX, Placebo
- Drug
- Lead sponsor
- Akero Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 46
- States / cities
- Chandler, Arizona • Glendale, Arizona • Tucson, Arizona + 38 more
- Conditions
- Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
- Interventions
- Efinopegdutide, Semaglutide, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 42
- States / cities
- Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 36 more
- Conditions
- NAFLD
- Interventions
- somatropin
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 29 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NAFLD, Metabolic Dysfunction-associated Steatotic Liver Disease, Metabolic Dysfunction-associated Steatohepatitis
- Interventions
- Efinopegdutide, Placebo
- Combination Product
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 33
- States / cities
- Chandler, Arizona • Flagstaff, Arizona • Peoria, Arizona + 27 more
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis
- Interventions
- non-applicable
- Other
- Lead sponsor
- The Geneva Foundation
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 826 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Fort Sam Houston, Texas
- Conditions
- Fatty Liver, Nonalcoholic Steatohepatitis
- Interventions
- Pioglitazone
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- SEL, Placebo to match SEL 6 mg, Placebo to match SEL 18 mg
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 883 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 128
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 93 more
- Conditions
- Nonalcoholic Fatty Liver Disease
- Interventions
- Saroglitazar Magnesium 4 mg, Placebo
- Drug
- Lead sponsor
- Zydus Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • La Jolla, California • San Francisco, California + 5 more
- Conditions
- Fatty Liver
- Interventions
- Glucophage (Metformin), Placebo
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, Steatosis of Liver
- Interventions
- Not listed
- Lead sponsor
- University of Oxford
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- NASH - Nonalcoholic Steatohepatitis, NASH, Exercise, Liver
- Interventions
- Exercise Intervention with use of El-Fit App
- Behavioral
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Non-Alcoholic Steatohepatitis (NASH)
- Interventions
- SEL, SIM
- Drug · Biological
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 26
- States / cities
- Palo Alto, California • San Diego, California • San Francisco, California + 21 more
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- solithromycin
- Drug
- Lead sponsor
- Melinta Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- Pioglitazone, Placebo
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2006
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Overweight or Obesity
- Interventions
- FT-4101, FT-4101 placebo, Deuterated Water
- Drug · Other
- Lead sponsor
- Forma Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 2
- States / cities
- Chula Vista, California • Montclair, California
- Conditions
- Nonalcoholic Steatohepatitis (NASH)
- Interventions
- Miricorilant 150 mg, Miricorilant 100 mg, Miricorilant 50 mg, Miricorilant 10 mg
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 9
- States / cities
- Chandler, Arizona • Tucson, Arizona • Panorama City, California + 6 more
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Liver Disease
- Interventions
- Efinopegdutide
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 36
- States / cities
- Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 27 more
- Conditions
- Non Alcoholic Steatohepatitis (NASH)
- Interventions
- Obeticholic Acid, Placebo
- Drug
- Lead sponsor
- Intercept Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 2,477 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 175
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 116 more
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Liver Diseases
- Interventions
- Vigorous-intensity interval training (VIIT)
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- ¹³C-Methacetin Breath Test, BMS-986036, BreathID MCS device
- Combination Product · Drug · Device
- Lead sponsor
- Meridian Bioscience, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Humble, Texas
- Conditions
- Nonalcoholic Steatohepatitis (NASH)
- Interventions
- BMS-986263, Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 29
- States / cities
- Chandler, Arizona • Phoenix, Arizona • La Jolla, California + 22 more
- Conditions
- Moderate Liver Impairment, Severe Liver Impairment
- Interventions
- BMS-986036
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida • San Antonio, Texas
- Conditions
- Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
- Interventions
- GSK4532990, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 80
- States / cities
- Homewood, Alabama • Chandler, Arizona • Mesa, Arizona + 68 more